HIV Prevention Trials Network

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

Retrieved on: 
Monday, October 16, 2023

As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.

Key Points: 
  • As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs.
  • Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy’s resistance profile.
  • The mental health outcomes reported by participants in BICSTaR over a two-year period will also be presented at EACS 2023.
  • Mental health impairments can further increase the risk of negative health outcomes at every stage of the HIV care continuum.

New Data Presented at the 2022 San Antonio Breast Cancer Symposium Shows Early Detection using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Retrieved on: 
Thursday, December 15, 2022

CARLSBAD, Calif., Dec. 15, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas.

Key Points: 
  • CARLSBAD, Calif., Dec. 15, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas.
  • The poster, titled "Bioimpedance spectroscopy monitoring reduces long-term clinical lymphedema risk" includes a Kaplan-Meier analysis of data from the PREVENT Trial to assess lymphedema progression-free survival in breast cancer patients who triggered for subclinical lymphedema and received intervention (n=209).
  • The analysis showed that there were statistically higher rates of lymphedema progression-free survival in patients screened for subclinical lymphedema using L-Dex compared to using tape measure, p = 0.021.
  • He continued, "Chronic lymphedema is a serious side effect of breast cancer treatment that dramatically impacts patients' quality of life in survivorship.

New Data Confirms Early Detection and Intervention of Lymphedema Improves Quality of Life for Breast Cancer Patients Who Avoid Chronic Lymphedema

Retrieved on: 
Thursday, October 20, 2022

CARLSBAD, Calif., Oct. 20, 2022 /PRNewswire/ -- ImpediMed Limited (ASX: IPD) is pleased to announce publication of results from the PREVENT trial showing that early detection and intervention of breast cancer-related lymphedema reduces the burden of chronic lymphedema on patients. The analysis also shows that L-Dex testing is more effective than tape measure at identifying the optimal time to intervene to stop lymphedema progression.

Key Points: 
  • CARLSBAD, Calif., Oct. 20, 2022 /PRNewswire/ --ImpediMed Limited (ASX: IPD) is pleased to announce publication of results from the PREVENT trial showing that early detection and intervention of breast cancer-related lymphedema reduces the burden of chronic lymphedema on patients.
  • The analysis also shows that L-Dex testing is more effective than tape measure at identifying the optimal time to intervene to stop lymphedema progression.
  • He continued, "Chronic BCRL takes a physical and emotional toll on breast cancer survivors leading to depression, reduced mobility, and infection risk.
  • This study showed that by stopping progression with early intervention, patients can avoid the burden of life-long lymphedema.

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women - Findings from HPTN 084 Study

Retrieved on: 
Thursday, July 28, 2022

New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through November 5, 2021).

Key Points: 
  • New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through November 5, 2021).
  • Participants were subsequently unblinded and continued their original randomized study regimen pending a protocol amendment to offer open-label CAB.
  • Empowering women with safe and effective PrEP options is critical to reducing HIV as a global health threat.
  • HPTN 084 enrolled 3,223 cisgender women at research sites in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, and Zimbabwe.

New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed's L-Dex® Technology and Intervention

Retrieved on: 
Tuesday, February 1, 2022

ImpediMed's PREVENT Trial demonstrated that patients with early detection using L-Dex and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure.

Key Points: 
  • ImpediMed's PREVENT Trial demonstrated that patients with early detection using L-Dex and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure.
  • The difference is statistically significant (p=0.016) as well as being clinically significant for patients and clinicians.
  • This represents an absolute reduction of 11.3% and relative reduction of 59% in lymphedema progression at three years.
  • If left untreated, lymphedema can become a chronic lifelong condition leading to life-threatening infections and a significant reduction in the patient's quality of life.

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Retrieved on: 
Monday, November 15, 2021

These CAMs enable the selection of a new pipeline candidate, which will be the second molecule in Antios' HBV portfolio.

Key Points: 
  • These CAMs enable the selection of a new pipeline candidate, which will be the second molecule in Antios' HBV portfolio.
  • "Unlike traditional CAMs, which target capsid assembly and disassembly, we believe these molecules may have an additional mechanism of action.
  • ATI-2173, Antios Therapeutics' lead once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate.
  • Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Retrieved on: 
Saturday, July 17, 2021

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.

Key Points: 
  • Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.
  • A corresponding trial in Europe, CARISEL, is examining the implementation of long-acting cabotegravir and rilpivirine, dosed every 2-months in certain European healthcare settings.
  • Marketing Authorisations for the long-acting regimen of cabotegravir and rilpivirine were granted by the European Medicines Agency in December 2020.
  • Sustainment of implementation strategies was assessed via surveys and semi-structured interviews of staff study participants as well as patient study participants.

HIV Prevention Trials Network Launches HPTN 094 (INTEGRA) Study

Retrieved on: 
Wednesday, June 9, 2021

Durham, N.C., June 09, 2021 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today the launch of HPTN 094 (INTEGRA) , a study to determine whether using mobile health units to deliver integrated health services for people with opioid use disorder (OUD) can improve HIV and substance use treatment and prevention.

Key Points: 
  • Durham, N.C., June 09, 2021 (GLOBE NEWSWIRE) -- The HIV Prevention Trials Network (HPTN) announced today the launch of HPTN 094 (INTEGRA) , a study to determine whether using mobile health units to deliver integrated health services for people with opioid use disorder (OUD) can improve HIV and substance use treatment and prevention.
  • The study aims to address the overlapping and intertwined public health crises of opioid addiction and HIV among PWID.
  • The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV.
  • The HPTN has collaborated with more than 85 clinical research sites in 19 countries to evaluate new HIV prevention interventions and strategies in populations with a disproportionate HIV burden.

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Retrieved on: 
Tuesday, May 4, 2021

With only six dosing days per year, long-acting cabotegravir would provide an option that eliminates the need for adherence to a daily pill.

Key Points: 
  • With only six dosing days per year, long-acting cabotegravir would provide an option that eliminates the need for adherence to a daily pill.
  • The trial design included an oral lead-in phase to assess tolerability to cabotegravir before administering the intramuscular injection.
  • This translated to an HIV incidence rate of 0.38% (95% confidence interval [CI] 0.20%-0.66%) in the cabotegravir group and 1.22% (95% CI 0.86%-1.66%) in the FTC/TDF group.
  • ISRs in HPTN 084 occurred more frequently in the cabotegravir arm (32%) vs. the FTC/TDF arm (9%), which received placebo injections.

Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19

Retrieved on: 
Tuesday, February 16, 2021

Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the initiation of a Phase 1 clinical trial evaluating its lead monoclonal antibody product candidate, ADG20.

Key Points: 
  • Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the initiation of a Phase 1 clinical trial evaluating its lead monoclonal antibody product candidate, ADG20.
  • Were very proud of the impressive work the team at Adagio has done, rapidly moving from lead identification and manufacturing into clinical trials within eight months.
  • We will be evaluating ADG20 across multiple clinical settings on a global basis from pre- and post-exposure prophylaxis to treatment.
  • Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs.